Skip to content
Kobo Biotech logo

Kobo Biotech

531541 BSE
₹3.62

Close ·

P/E
Not meaningful: loss-making over the last twelve months
View as Markdown
MCP
Close 4 Nov 2026 ₹3.62 +0.51 +16.4% 1Y
Start ₹3.11

Key Fundamentals

MicrocapChemicals & PetrochemicalsChemicals

Price-based figures at the close · TTM

ROCE
−126.00%
Debt to Equity
Not meaningful: shareholders’ equity is negative
EPS (TTM)
−₹2.10
Book Value
−₹57.98
Market Cap
—
P/E (TTM)
Not meaningful: loss-making over the last twelve months
P/B
Not meaningful: book value is negative
ROE
Not meaningful: shareholders’ equity is negative
Dividend Yield
0.00%
EBITDA
−₹70.00 L
52W High
₹9.99
52W Low
₹1.99

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

—

Insufficient data

Not enough numeric coverage across the required pillars to publish a Tapetide Score for this stock.

Coverage 52%

Key Insights

No strengths listed

Weaknesses

1
  • Company has low interest coverage ratio.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1216
OscillatorsStrong Bullish216
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
27.75
Bullish
MACD (12,26,9)
−0.22
Bearish
SMA (50)
4.43
Bearish
SMA (200)
4.40
Bearish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2025; 1Y: fiscal year to Mar 2025 against Mar 2024.

Revenue

Revenue growth by window
10Y−100.00%
5YZero base
3YZero base
1YZero base

Net profit

Net profit growth by window
10YLoss narrowed by ₹25.03 Cr
5YLoss narrowed by ₹15.78 Cr
3YLoss narrowed by ₹10 Cr
1YLoss widened by ₹0.30 Cr

Operating cash flow

Operating cash flow growth by window
10Y−14.19%
5Y−22.00%
3Y−64.54%
1YTiny base

Operating margin· change in pp

Operating margin growth by window
10YNo sales
5YNo sales
3YNo sales
1YNo sales

Trailing twelve months: The latest quarterly results are more than a year old.

Revenue by year

Revenue by year, ₹ crore
Mar 2016₹32.54 Cr
Mar 2017₹0.00 Cr
Mar 2018₹0.00 Cr
Mar 2019₹0.00 Cr
Mar 2020₹0.00 Cr
Mar 2021₹0.00 Cr
Mar 2022₹0.00 Cr
Mar 2023₹0.00 Cr
Mar 2024₹0.00 Cr
Mar 2025₹0.00 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2016−₹16.46 Cr
Mar 2017−₹19.24 Cr
Mar 2018−₹23.92 Cr
Mar 2019−₹24.46 Cr
Mar 2020−₹21.01 Cr
Mar 2021−₹19.23 Cr
Mar 2022−₹15.23 Cr
Mar 2023−₹5.55 Cr
Mar 2024−₹4.93 Cr
Mar 2025−₹5.23 Cr

Quarterly Results

₹ Cr

Results for the period ended Sep 2024 were due by 14 Nov 2024 and are not in this table yet.

531541 quarterly results, ₹ crore
Particulars Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Sales
0
0
0
0
0
0
0
0
0
0
0
0
0
Expenses
0.27
0.7
0.3
9.24
0.34
0.21
0.17
0.79
0.23
0.2
0.2
0.25
0.34
Operating Profit
−0.27
−0.7
−0.3
−9.24
−0.34
−0.21
−0.17
−0.79
−0.23
−0.2
−0.2
−0.25
−0.34
Other Income
0.02
0
0
0
0.02
0
0
0
0.02
0
0
0
0.02
Interest
0
0.13
0
0
0
0
0
0
0
0
0
0
0
Depreciation
1.35
1.03
1.04
1.18
1.15
0.89
1.03
1
1.01
1.02
1.03
1.01
1.01
PBT
−1.6
−1.86
−1.34
−10.42
−1.47
−1.1
−1.2
−1.79
−1.22
−1.22
−1.23
−1.26
−1.33
Tax %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
Net Profit
−1.6
−1.86
−1.35
−10.42
−1.47
−1.1
−1.19
−1.79
−1.23
−1.22
−1.23
−1.26
−1.33
EPS (₹)
−0.67
−0.78
−0.57
−4.37
−0.62
−0.46
−0.5
−0.75
−0.52
−0.51
−0.52
−0.53
−0.56

Profit & Loss

₹ Cr
531541 profit and loss, annual, ₹ crore
Particulars Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Sales
56.89
29.05
32.54
0
0
0
0
0
0
0
0
0
Expenses
61.34
38.51
27.74
4.05
3.02
1.72
0.69
2.79
10.51
1.5
0.88
1.24
Operating Profit
−4.45
−9.46
4.8
−4.05
−3.02
−1.72
−0.69
−2.79
−10.51
−1.5
−0.88
−1.24
OPM %
−7.82%
−32.56%
14.75%
—
—
—
—
—
—
—
—
—
Other Income
0.18
2.6
0.42
6
0.04
−2.15
0.03
0.04
0.02
0.02
0.02
0.08
Interest
18.14
15.62
14.37
14.41
14.5
14.44
14.47
10.84
0.13
0
0
0
Depreciation
9.62
7.78
7.31
6.78
6.44
6.15
5.88
5.64
4.61
4.07
4.07
4.07
PBT
−32.03
−30.26
−16.46
−19.24
−23.92
−24.46
−21.01
−19.23
−15.23
−5.55
−4.93
−5.23
Tax %
1.69%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
Net Profit
−32.57
−30.26
−16.46
−19.24
−23.92
−24.46
−21.01
−19.23
−15.23
−5.55
−4.93
−5.23
EPS (₹)
−14.48
−13.45
−6.94
−8.08
−10.04
−10.27
−8.82
−8.07
−6.39
−2.33
−2.07
−2.2
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%

Balance Sheet

₹ Cr
531541 balance sheet, annual, ₹ crore
Particulars Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Equity Capital
22.5
22.5
23.73
23.83
23.83
23.83
23.83
23.83
23.83
23.83
23.83
23.83
Reserves
22.07
−8.83
−17.3
−42.41
−66.33
−90.79
−112
−131
−146
−152
−157
−162
Borrowings
137
142
153
208
222
236
251
261
141
140
140
140
Other Liabilities
97.45
95.74
101
63.2
66.48
70.04
73.54
77.26
60.89
63.47
64.62
70.04
Total Liabilities
279
252
260
252
246
239
236
231
79.18
75.33
71.4
71.59
Fixed Assets
104
95.1
87.79
81.01
74.56
68.42
62.54
56.91
41.66
37.59
33.52
29.44
CWIP
2.25
2.25
2.25
2.25
2.25
2.25
2.25
2.25
0
0
0
0
Investments
12.19
12.19
12.19
12.19
12.19
12.19
12.19
12.19
0
0
0
0
Other Assets
161
142
158
157
157
157
159
159
37.52
37.74
37.88
42.15
Total Assets
279
252
260
252
246
239
236
231
79.18
75.33
71.4
71.59

Cash Flow

₹ Cr
531541 cash flow, annual, ₹ crore
Particulars Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating
11.02
19.32
5.62
32.3
31.47
20.95
14.48
2.51
93.76
0.87
0.2
4.18
Investing
−4.71
0
0
0
0
0
0
0
25.09
0
0
0
Financing
−7
−20.5
−5.27
−32.76
−31.47
−20.95
−14.47
−1.08
−120
−0.87
−0.15
0
Net Cash Flow
−0.69
−1.18
0.35
−0.46
0
0
0
1.43
−1.43
0
0.05
4.18
Free Cash Flow
6.31
19.32
5.62
32.3
31.47
20.95
14.48
2.51
107
0.87
0.2
4.18
CFO/OP
−260
−204
117
−798
−1,042
−1,218
−2,099
−90
−892
−58
−23
−337

Ratios

531541 financial ratios, annual
Particulars Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
419
706
1,007
—
—
—
—
—
—
—
—
—
Inventory Days
585
896
1,039
—
—
—
—
—
—
—
—
—
Days Payable
405
660
1,093
—
—
—
—
—
—
—
—
—
Cash Conversion Cycle
599
943
953
—
—
—
—
—
—
—
—
—
Working Capital Days
26.63
−277
−251
—
—
—
—
—
—
—
—
—
ROCE %
−7.12%
−10.18%
−1.33%
−2.77%
−5.11%
−4.49%
−3.94%
−5.31%
−17.6%
−36.82%
−52.9%
−125.57%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Kobo Biotech insights

60 extracted metrics across FY09–FY25.

Shareholding Pattern

As of Sep 2026

  • Public 47.68%
  • Promoters 44.95%
  • Others 7.37%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Kobo Biotech

What does Kobo Biotech Ltd do?
Incorporated in 1993, Kobo Biotech Ltd is in the pharmaceutical business
Where is Kobo Biotech Ltd (KOBO) listed?
Kobo Biotech Ltd trades under code 531541 on the BSE.
Which sector does Kobo Biotech Ltd belong to?
Kobo Biotech Ltd is classified under the Chemicals sector, in the Commodity Chemicals industry.
What is the 52-week high and low of Kobo Biotech Ltd?
Over the last 52 weeks Kobo Biotech Ltd has traded between ₹1.99 and ₹9.99 as of 4 Nov 2026.

Company Information

Incorporated in 1993, Kobo Biotech Ltd is in the pharmaceutical business

Website avonlifesciences.com
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531541.md for Kobo Biotech Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Chemical & Petrochemical stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month